ArticleSubstance abuse2023
Will the End of the X-Waiver Expand Access to Buprenorphine Treatment? Achieving the Full Potential of the 2023 Consolidated Appropriations Act.
Article in Substance abuse, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Barriers and facilitators to scaling up medications for opioid use disorder in Kentucky: qualitative perspectives of treatment organization staff.Substance abuse treatment, prevention, and policy · 2025Trial
- Receipt of Pharmacotherapy and Association with Healthcare Utilization Among US Adults with Alcohol or Opioid Use Disorder, 2022-2023.Journal of general internal medicine · 2026Article
- Policy and Payment Factors Influencing Adoption of Low-Barrier Buprenorphine Treatment.JAMA network open · 2026Article
- Structural and Policy Determinants of Access to Medications for Opioid Use Disorder Among Pregnant People in U.S. Jails.International journal of environmental research and public health · 2026Article
- Navigating opioid use disorder treatment for pregnant and parenting people: composite narratives for policy action.Substance abuse treatment, prevention, and policy · 2026Article
- Availability of Treatment for Alcohol and Opioid Use Disorders Among Accountable Care Organization Participants.Psychiatric services (Washington, D.C.) · 2026Article
- Words matter: Stigmatizing language in medical records of individuals electing medication for opioid use disorder.Drug and alcohol dependence · 2025Article
- Hospital Provider's Perspectives on MOUD Initiation and Continuation After Inpatient Discharge.Journal of general internal medicine · 2025Article
- Clinical pharmacist practitioners prescribing of buprenorphine for opioid use disorder.Drug and alcohol dependence · 2025Article
- Buprenorphine: Applications in Oncology and Palliative Care.Clinical journal of oncology nursing · 2025Article
- Barriers and facilitators to prescribing buprenorphine for treating opioid use disorder among emergency department and other practice setting physicians.AIMS public health · 2025Article
- Scaling up medications for opioid use disorder in Kentucky: Qualitative perspectives of treatment organizations.Research square · 2024Article
- Implementation outcomes from a pilot study of training probation officers to deliver contingency management for emerging adults with substance use disorders.Journal of substance use and addiction treatment · 2024Article
- Disparities in Access to Highly Rated Skilled Nursing Facilities among Medicare Beneficiaries with Opioid Use Disorder.Journal of the American Medical Directors Association · 2024Observational
- Policies, adaptations, and ongoing challenges to naloxone, buprenorphine and nonprescription syringe access across four-states: Findings from an environmental scan and key informant interviews.Drug and alcohol dependence reports · 2024Article
- Perspectives on Admissions and Care for Residents With Opioid Use Disorder in Skilled Nursing Facilities.JAMA network open · 2024Article
- The Roles, Activities, and Opportunities of Clinical Pharmacists in a National Initiative to Improve Office-Based Buprenorphine Care.Substance use : research and treatmentArticle
- Listings of Buprenorphine Offering by Substance Use Disorder Treatment Facilities and Waivered Clinician From July 2019 to May 2021.Journal of addiction medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The 2023 Consolidated Appropriations Act repealed the special waiver for prescribing buprenorphine to patients with opioid use disorder, a bipartisan goal long sought by advocates. The change has symbolic importance in recognizing that buprenorphine is a mainstream medical treatment. We argue that the maximum potential of the law can be achieved by addressing three bottlenecks. First, it is important that new training requirements for all controlled substances prescribers be grounded in scientific principles of addiction treatment and are robustly evaluated to ensure they meet quality standards. Second, even with the elimination of the waiver, there are potential constraints from state law such as state-specific requirements that practitioners require counseling or obtain a separate credential, and many states also have limiting scope of practice regulations. We recommend that these requirements are eased wherever possible to improve treatment access. Third, it is critical to build onramps to treatment in settings such as primary care, hospitals, and correctional facilities. While we anticipate that buprenorphine prescribing will primarily occur in high-volume practices, there is the potential to activate a broader workforce to serve as entry points to care. We conclude that the stage is set for significant increases in lifesaving treatment but the difficult task ahead is ensuring that the resources and training are available to build strong capacity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.